Tocilizumab [375823-41-9]

Katalog-Nummer HY-P9917-1mg

Size : 1mg

Marke : MedChemExpress

Contact local distributor :


Telefonnummer : +1 850 650 7790

Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr. : 375823-41-9

This product is a controlled substance and not for sale in your territory.

Based on 23 publication(s) in Google Scholar

Alle Interleukin Related Isoform-spezifische Produkte anzeigen:

Alle Isoformen anzeigen
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22
Beschreibung

Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis[1]. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease)[4].

Isotype

Human IgG1 kappa

Recommend Isotype Controls

Human IgG1 kappa, Isotype Control

Species

Humanized

IC50 & Target[1][2]

IL-6

 

In Vitro

Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1-100 ng/mL; 24 hours, 48 hours) inhibits the cell proliferation (growth rate) in a dose-dependent manner, growth rate by HACM is reduced almost completely by 100 ng/mL tocilizumab[2].
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (0.001-10,000 μg/ml; 2 days) inhibits Ba/F3-gp130-IL-6R cell proliferation stimulated with hIL-6 with an IC50 of 13.5 ng/ml[1].
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1 μM; 6 hours) reduces the phosphorylation of STAT3 in vitro consistent with in vivo SAS cells[3].
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (1-5 μM; 24 hours) significantly reduces VEGF mRNA expression in SAS cells with serum-free medium[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[2]

Cell Line: Human-derived HARA-B cells
Concentration: 1 ng/mL, 10 ng/mL, and 100 ng/mL
Incubation Time: 24 hours, 48 hours
Result: Inhibited the IL-6R expressed on human-derived HARA-B cells.

Cell Cytotoxicity Assay[1]

Cell Line: Ba/F3-gp130-IL-6R cells
Concentration: 0.001–10000 μg/ml
Incubation Time: 2 days
Result: Inhibited Ba/F3-gp130-IL-6R cell proliferation.

Western Blot Analysis[3]

Cell Line: SAS cells
Concentration: 1 μM
Incubation Time: 6 hours
Result: Reduced the phosphorylation of STAT3.

RT-PCR[3]

Cell Line: SAS cells
Concentration: 1-5 μM
Incubation Time: 24 hours
Result: Reduced VEGF mRNA expression.
In Vivo

Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intravenous injection; 1.0 mg/100 μL; twice a week, three weeks) decreases the volume of each metastatic focus in tocilizumab-injected mouse brains[2].
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intraperitoneal injection;100 μg/mL, every 48 hours; 20days) suppresses OSCC progression and suppresses Tumor Angiogenesis[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: A brain metastasis model of lung tumor cells by inoculating HARA-B cells in nude mice[2]
Dosage: 1.0 mg/100 μL
Administration: Intravenous injection; 1.0 mg/100 μL; twice a week, three weeks
Result: Led the volume of each metastatic focus significantly smaller.
Animal Model: SCID mice with SAS cells[3]
Dosage: 100 μg/mL
Administration: Intraperitoneal injection;100 μg/mL; every 48 hours; 20days
Result: Suppressed the growth of advanced tumors.
Klinische Studie
CAS. Nr.

375823-41-9

Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Tocilizumab]

Versand

Shipping with dry ice.

Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Format
  • Human IgG1 kappa
Biological Activity
  • Flow cytometry analysis of IL-6R expression U937 cells labelling IL-6R with Tocilizumab at 10nM (Red), 20ng/mL of FcγRI (CD64), FcγRII (CD32), and FcγRIII (CD16) were added to block the binding of Fc of antibody to cells respectively. Goat anti human IgG Fc(Alexa Fluor488) was used as the secondary antibody at 1/400 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).
Reinheit & Dokumentation

Purity: 99.67%

Verweise
  • [1]. Garbers C, et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem. 2011 Dec 16;286(50):42959-70.  [Content Brief]

    [2]. Mami Noda, et al. IL-6 Receptor Is a Possible Target against Growth of Metastasized Lung Tumor Cells in the Brain. Int J Mol Sci. 2013 Jan; 14(1): 515–526.  [Content Brief]

    [3]. Shinriki S, et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivogrowth of human oral squamous cell carcinoma. Clin Cancer Res. 2009 Sep 1;15(17):5426-34.  [Content Brief]

    [4]. Chi Zhang, et al. Cytokine Release Syndrome in Severe COVID-19: Interleukin-6 Receptor Antagonist Tocilizumab May Be the Key to Reduce Mortality. Int J Antimicrob Agents. 2020 May;55(5):105954.  [Content Brief]

  • [1]. Garbers C, et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem. 2011 Dec 16;286(50):42959-70.

    [2]. Mami Noda, et al. IL-6 Receptor Is a Possible Target against Growth of Metastasized Lung Tumor Cells in the Brain. Int J Mol Sci. 2013 Jan; 14(1): 515–526.

    [3]. Shinriki S, et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivogrowth of human oral squamous cell carcinoma. Clin Cancer Res. 2009 Sep 1;15(17):5426-34.

    [4]. Chi Zhang, et al. Cytokine Release Syndrome in Severe COVID-19: Interleukin-6 Receptor Antagonist Tocilizumab May Be the Key to Reduce Mortality. Int J Antimicrob Agents. 2020 May;55(5):105954.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Tocilizumab Related Classifications

  • Inflammation/Immunology Cancer
  • Cancer Targeted Therapy Cancer Immunotherapy
  • Inhibitory Antibodies
  • Immunology/Inflammation
  • Interleukin Related

Die Formel zur Berechnung von Molaritäten

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)

Diese Gleichung wird häufig abgekürzt als: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs

Keywords:

Tocilizumab375823-41-9Anti-Human IL6R, Humanized AntibodyInterleukin RelatedILantibodyIL-6RNeutralizingrheumatoidarthritisSARS-CoV-2coronavirus diseaserespiratory failuredyspnoeaCOVID-19Inhibitorinhibitorinhibit

Sie könnten auch an folgenden Produkten interessiert sein:



Katalog-Nummer
Beschreibung
Cond.
Preis zzgl. MwSt.
A10970-1
 100ug/vial